Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026)
Grown Rogue International (GRUSF) recorded quarterly Cash from Financing Activities of $2.7 million in Q1 2026, up 100.0% quarter-over-quarter from -$10136.9 billion in Q4 2025, and down 41.3% on a YoY basis from $4.5 million in Q1 2025.
Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Grown Rogue International's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 41.3% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at -$10136.9 billion (down 299677217.61% YoY), while the FY2025 annual figure was $9.8 million, up 117.4% from the prior year.
- Cash from Financing Activities was $2.7 million for Q1 2026 at Grown Rogue International, up from -$10136.9 billion in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $4.5 million in Q1 2025 to a low of -$10136.9 billion in Q4 2025.
- Historically, Cash from Financing Activities has averaged -$921.5 billion across 5 years, with a median of -$200531.9 in 2024.
- Biggest YoY gain for Cash from Financing Activities was 54.82% in 2025; the steepest drop was 3604482049.28% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$558849.0 in 2022, then surged by 543.08% to $2.5 million in 2023, then tumbled by 111.36% to -$281230.6 in 2024, then tumbled by 3604482049.28% to -$10136.9 billion in 2025, then jumped by 100.0% to $2.7 million in 2026.
- The last three Cash from Financing Activities figures came in at $2.7 million (Q1 2026), -$10136.9 billion (Q4 2025), and -$308664.9 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Grown Rogue International | - | - | 3.96 Mn | 2.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.67 Mn |
| Mar 31, 2026 | 2.67 Mn |
| Dec 31, 2025 | -10,136.91 Bn |
| Dec 31, 2025 | -10,136.91 Bn |
| Jun 30, 2025 | -308,664.89 |
| Jun 30, 2025 | -308,664.89 |
| Mar 31, 2025 | 4.55 Mn |
| Mar 31, 2025 | 4.55 Mn |
| Dec 31, 2024 | -281,230.64 |
| Dec 31, 2024 | -281,230.64 |
| Sep 30, 2024 | -200,531.89 |
| Sep 30, 2024 | -200,531.89 |
| Jun 30, 2024 | -683,206.97 |
| Jun 30, 2024 | -683,206.97 |
| Oct 31, 2023 | 2.48 Mn |
| Oct 31, 2023 | 2.48 Mn |
| Jul 31, 2023 | 3.08 Mn |
| Jul 31, 2023 | 3.08 Mn |
| Apr 30, 2022 | -558,849.00 |
| Apr 30, 2022 | -558,849.00 |